Puma Biotechnology | PBYI - Profitto Lordo Sulle Vendite





Profitto Lordo Sulle Vendite Cambiamento Data
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amgen USD 6.89B 415M 2025-12
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Exelixis USD 590.86M 18.68M 2026-03
Gilead Sciences USD 5.52B 791M 2026-03
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Incyte USD 1.17B 217.51M 2026-03
MacroGenics USD 31.11M 30.14M 2025-12
Moderna USD -566M 792M 2026-03
Novartis USD 10.07B 184M 2026-03
Pfizer USD 11.04B 1.24B 2026-03
PTC Therapeutics USD 232.94M 84.56M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
Takeda JPY 688.84B 101.71B 2026-03
TG Therapeutics USD 171.41M 16.98M 2026-03
Ultragenyx Pharmaceutical USD 106M 72M 2026-03
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03